前收市價 | 3.3600 |
開市 | 3.3600 |
買盤 | 3.8000 |
賣出價 | 5.3000 |
拍板 | 42.50 |
到期日 | 2024-10-18 |
今日波幅 | 3.3600 - 3.3600 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 413 |
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
On Thursday, the European Commission granted marketing authorization under exceptional circumstances and maintained orphan designation for Biogen Inc’s (NASDAQ:BIIB) Qalsody (tofersen) for amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 gene (SOD1-ALS). Qalsody is the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND). SOD1-ALS is an ultra-rare genetic form of ALS estimated to affe
Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics are part of the Zacks top Analyst Blog.